• Pazopanib and ATRX-Deficient Glioma: Evidence

  2026-10-13

  A 2022 study links ATRX deficiency in high-grade glioma cells with greater sensitivity to several RTK and PDGFR inhibitors, but the evidence is class-level and does not establish pazopanib as an effective or clinically validated ATRX-selective treatment.

• Mouse Tissue Lysis Kit K1038: Evidence Overview

  2026-10-13

  The Mouse Tissue Lysis Kit (K1038), supplied by APExBIO, is documented as a research-use tissue lysis product intended to support direct PCR-based mouse genotyping. The available evidence is limited to the supplier’s product description; no matched reference paper or independent performance study was provided.

• (S)-(+)-Dimethindene Maleate: Evidence Scope

  2026-10-12

  The APExBIO product listing identifies (S)-(+)-Dimethindene maleate as a defined maleate salt described as an M2 muscarinic receptor and histamine H1 receptor antagonist. With no matched research paper available, its relevance is limited to a documented product identity and a conceptual role in receptor pharmacology—not independently verified mechanisms, outcomes, or model-specific performance.

• Reversible Biotinylation and Cell-Surface Biology

  2026-10-12

  Sulfo-NHS-SS-Biotin provides a conceptual bridge between reversible protein labeling and questions about cell-surface organization. The supplied preprint reports cell-surface RNA-binding-protein and glycoRNA nanodomains associated with TAT peptide entry, but it does not establish that this product was used or that the findings generalize across cell types.

• Sulfo-Cy7 NHS Ester Product Overview

  2026-10-10

  APExBIO lists Sulfo-Cy7 NHS Ester, SKU A8109, as a sulfonated near-infrared fluorescent dye for conceptual amino-group labeling of proteins and peptides. No matched paper evidence was supplied, so catalog specifications and application claims are not independent validation.

• DDIT4 Links Microplastics to Kidney Organoid Injury

  2026-10-09

  Wang et al. report that 1 μm polystyrene microplastics impair nephron development in human pluripotent stem cell-derived kidney organoids through a DDIT4-associated autophagy and apoptosis response. The study is notable for connecting organoid-level developmental injury with a candidate molecular mediator, while its short-term in vitro design limits direct extrapolation to human environmental exposure.

• Celastrol, CAV-1, and Mitochondrial Cholesterol

  2026-10-09

  A 2026 Phytomedicine study identifies a mechanistic link between celastrol, CAV-1/SCP2-dependent cholesterol trafficking, mitochondrial stress, and mitophagy in liver cancer models. Its findings support organelle-specific cholesterol metabolism as a research direction, while remaining preclinical and limited by the available model and reporting scope.

• NOTCH3 R545C and CADASIL Vascular-Neuronal Dysfunction

  2026-10-08

  A 2026 Neurobiology of Disease study introduces a CRISPR/Cas9-generated mouse model carrying the NOTCH3 p.R545C mutation, orthologous to the human East Asian-enriched p.R544C variant. The model links age-dependent cognitive impairment with vascular barrier disruption, neuroinflammatory signatures, synaptic dysfunction, and hippocampal structural changes, while also defining important boundaries for interpreting preclinical CADASIL evidence.

• LNP Delivery of ABE8e for COL7A1 Correction

  2026-10-08

  A 2024 Journal of Investigative Dermatology study examined lipid nanoparticles as carriers for the adenine base editor ABE8e in dystrophic epidermolysis bullosa fibroblasts, targeting pathogenic COL7A1 variants in vitro. Its significance lies in connecting nonviral mRNA delivery with sequence-level correction, while the in vitro design means that delivery, editing specificity, functional restoration, and clinical relevance require further validation.

• ORAI2 and Early Postirradiation Salivary Fibrosis

  2026-10-07

  A 2025 study identifies ORAI2-mediated store-operated calcium entry as an important driver of early postirradiation salivary-gland fibrosis and proposes an ORAI2/JNK/NFAT1/TGF-β1 signaling axis. The findings connect calcium signaling to fibrotic remodeling and improved salivary flow in a mouse model, while also highlighting the limits of pharmacologic and preclinical evidence.

• Sulfo-NHS-SS-Biotin: Reading Cell-Surface Evidence

  2026-10-07

  Sulfo-NHS-SS-Biotin offers a reversible way to interrogate amine-bearing proteins at the cell surface. This article explains how its chemistry can inform glycoRNA–RNA-binding protein research while distinguishing direct findings from interpretation and experimental limitations.

• Rimonabant (SR141716): Research Context and Evidence

  2026-10-06

  Rimonabant is a selective CB1 antagonist used as a pharmacological probe in endocannabinoid-system, appetite-regulation, and obesity research. The supplied evidence supports mechanistic investigation but does not establish clinical efficacy or broader therapeutic applications.

• GS967 and Cardiac Late Sodium Current Research

  2026-10-06

  GS967 is a research compound used to investigate pathological late sodium current in cardiac models. Evidence from a 2024 aging study supports a mechanistic relationship between Nav1.5 Ser571 phosphorylation, increased late sodium current, delayed ventricular repolarization, and impaired relaxation, while direct evidence for GS967 in human disease remains limited.

• Rimonabant (SR141716): Research Context and Evidence

  2026-10-05

  Rimonabant, also known as SR141716, is a selective CB1 receptor antagonist used as a research tool for studying endocannabinoid signaling, food reward, energy balance, and cannabinoid withdrawal. Evidence supports its value as a mechanistic probe, particularly in animal models, but findings do not establish clinical benefit or justify therapeutic use. This overview compares receptor pharmacology with behavioral evidence, highlights sex-dependent withdrawal findings, and explains major limitations involving model choice, psychiatric safety, and source provenance.

• Sequencing Waldenström Therapies Through Genomics

  2026-10-05

  This 2021 review argues that therapy selection in Waldenström macroglobulinemia should integrate clinical presentation, patient priorities, prior treatment context, and MYD88/CXCR4 genomic status rather than follow a single universal sequence. Its key contribution is a genotype-informed framework that places ibrutinib, chemoimmunotherapy, proteasome inhibitor regimens, transplantation, and investigational agents such as mavorixafor within a disease-specific decision landscape.

8569 records 1/572 page Next 12345 下5页 Last page